Options & Issues in Anemia Management

ANNA Lunch Symposium
April 2003
Access to this symposium is free, but you must first be a registered FREE ZONE user of HDCN. If not already an HDCN FREE ZONE user, please register at this link and select a username and password.
Does Correction of Anemia Improve Vascular Access Outcomes?
Lesley C. Dinwiddie, MSN, RN, FNP, CNN
IV Iron Outside the Dialysis Unit
Chaim Charytan, MD
Anemia Management in a PD-Unit: A Real-World Experience
Erin E. Lundell, RN
Is IV Iron Safe in Patients With Chronic Kidney Disease?
George R. Aronoff, MD, FACP

Activity purpose/goal: Increase the knowledge base of those caring for anemic hemodialysis patients.

After participating in this program, the learner should be able to:
  1. Identify the range of IV iron doses available to manage patients with anemia, iron deficiency and CKD.
  2. Describe maintenance iron protocols as practiceal and effective in peritoneal dialysis patients
  3. State the safety of IV iron administration given in doses within K/DOQI guidelines
  4. Identify infections in dialysis patients that have been linked to catheters, previous bacteremia, anemia, and immune suppression.
Lesley C. Dinwiddie, MSN, RN, FNP, CNN
Independent Consultant for Vascular Access

Chaim Charytan, MD
Associate Professor of Medicine
Chief, Renal Division
New York Hospital Medical Center of Queens
Clinical Professor of Medicine
Cornell University College of Medicine
Flushing, NY

Erin E. Lundell, RN
Program Director
Gambro Healthcare Greater Daytona
Daytona Beach, FL

George R. Aronoff, MD, FACP
Professor of Medicine and Pharmacology
Chief, Division of Nephrology
University of Louisville School of Medicine
Louisville, KY

The series of talks is approved for 1.5 Contact Hours by the American Nephrology Nurses' Association (ANNA) .
Date of Original Release: August, 2003
CE Credit Eligible Through: August, 2004
Contact Hours/Completion Time: 1.5
Target Audiences: Nephrology nurses and technicians.
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the linked abstracts in the post-test, answer feedback material.

Chronic kidney disease affects 30-40 million Americans, of whom several hundred thousand require renal replacement therapy. These selected lectures will allow nephrology nurses, pharmacists, and technicians to obtain up-to-date information about issues related to care of renal patients.

This continuing education activity is based on an approved Satellite Symposium which took place at the American Nephrology Nurses' Association (ANNA) 2003 Annual Meeting, and is approved by ANNA, East Holley Avenue, Box 56, Pitman, New Jersey 08071-0056, an accredited approver by the American Nurse Credentialing Center Commission on Accreditation (ANCC-COA). ANNA is an approved provider of CE to nursing by the California Board of Registered Nursing, BRN Provider No. 00910, the Alabama Board of Nursing, BRN Provider No. PO324, and the Kansas State Board of Nursing, Provider No. LT0148-0738. This course offering is applicable for RN and LPN licensure in Kansas. Licensees in the states of CA, AL, and KS must retain this certificate for four years after the CE activity is completed. Other mandatory CE states may have different record keeping requirements. Please be aware of your state's procedure.

The activity provider is HDCN, 15W560 89th St., Hinsdale, IL 60527.

The American Nephrology Nurses' Association, as well as HDCN have conflict of interest policies that require course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

L. Dinwiddie discloses no financial conflicts of interest having to do with the material being discussed.
Dr. Charytan has received research funding, honoraria, or served on an advisory board for Amgen, Ortho, Am Regent, Ortho Biotech.
E . Lundell discloses no financial conflicts of interest having to do with the material being discussed.
Dr. Aronoff has received research funding, honoraria, or served on an advisory board for American Regent, Amgen, Astra-Zeneca, Aventis, Boehringer-Ingelheim, Eli Lilly, Merck, Novartis, Ortho Biotech, Clarke-Davis, Pfizer, Pharmacia-Upjohn, Schein, Solvay .
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The American Nephrology Nurses' Association, and HDCN do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This educational activity is supported by an educational grant from American Regent Inc.
This activity has been planned and produced in accordance with CE Guidelines and Policies.
This educational activity is based on an official ANNA lunch symposium, but the program was not planned by the ANNA Program Committee.